National Cancer Institute (NCI): Melanoma, Cutaneous Malignant trials

The registry lists 21 Melanoma, Cutaneous Malignant studies with National Cancer Institute (NCI) as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 10Phase 2 9Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Genetics Branch Eligibility Screening SurveyNot yet recruitingNCT07005297
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
• MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00866177Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989559Phase 1
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Molecular Epidemiology of Cutaneous Malignant MelanomaCompletedNCT00341991
• Natural History Study of Moles and Suspicious MelanomaCompletedNCT00288938